EASEE® is an effective and well-tolerated treatment approach

65% responder rate, 68% median seizure reduction after two years of stimulation

Long-term results suggest that epicranial Focal Cortex Stimulation with the EASEE® systems is an effective and well tolerated new treatment approach for patients with pharmacoresistant focal epilepsy.

81% of the patients who had started stimulation continued FCS treatment over the period of 2 years.
The responder rate was 41.4% after 1 year (n = 29) and 65.4% after 2 years (n = 26).

The median monthly seizure frequency decreased from 12/months to 8/month after one year and to 5/month after 1.5 and 2 years.
This corresponds to a median reduction in seizure frequency of 33% after 12 months (n = 29) and 68% after 18 and 24 months (n = 26).

65,4% responder rate

68% median seizure reduction

Source: „Long-term outcome of epicranial Focal Cortex Stimulation with the EASEE® system in pharmacoresitant focal epilepsy”, Schulze-Bonhage et al. 2024

Source: „Focal Cortex Stimulation with a Novel Implantable Device and Antiseizure Outcomes in 2 Prospective Multicenter Singel-Arm Trials”, Schulze-Bonhage et al. 2023

Patients benefit from a reduction in seizures

In the adjacent image, each bar represents a patient in the EASEE® II and PIMIDES I studies. All bars pointing to the left indicate seizure reduction. Bars pointing to the right represent patients who experienced an increase in their seizures in the first six months. Overall, a seizure reduction was achieved in 87.5% of all patients. The four lower bars represent patients who became seizure-free.